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Kidney involvement appears to be frequent in coronavirus disease 2019 (COVID-19).
Despite this, information concerning renal involvement in COVID-19 is still scarce.
Several mechanisms appear to be involved in the complex relationship between the
virus and the kidney. Also, different morphological patterns have been described in
the kidneys of patients with COVID-19. For some authors, however, this association
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may be just a coincidence. To investigate this issue, we propose assessing renal
morphology associated with COVID-19 at the renal pathology reference center of
federal university hospitals in Brazil. Data will come from a consortium involving 17
federal university hospitals belonging to Empresa Brasileira de Serviços Hospitalares
(EBSERH) network, as well as some state hospitals and an autopsy center. All biopsies
will be sent to the referral center for renal pathology of the EBSERH network. The
data will include patients who had coronavirus disease, both alive and deceased,
with or without pre-existing kidney disease. Kidney biopsies will be analyzed by
light, fluorescence, and electron microscopy. Furthermore, immunohistochemical (IHC)
staining for various inflammatory cells (i.e., cells expressing CD3, CD20, CD4, CD8,
CD138, CD68, and CD57) as well as angiotensin-converting enzyme 2 (ACE2) will be
performed on paraffinized tissue sections. In addition to ultrastructural assays, in situ
hybridization (ISH), IHC and reverse transcription-polymerase chain reaction (RT-PCR)
will be used to detect Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2)
in renal tissue. For the patients diagnosed with Collapsing Glomerulopathy, peripheral
blood will be collected for apolipoprotein L-1 (APOL1) genotyping. For patients with
thrombotic microangiopathy, thrombospondin type 1 motif, member 13 (ADAMTS13),
antiphospholipid, and complement panel will be performed. The setting of this study is
Brazil, which is second behind the United States in highest confirmed cases and deaths.
With this complete approach, we hope to help define the spectrum and impact, whether
immediate or long-term, of kidney injury caused by SARS-CoV-2.
Keywords: COVID-19, SARS-CoV-2, glomerulopathy, kidney injury, collapsing glomerulopathy, thrombotic
microangiopathy
BACKGROUND
The coronavirus disease 2019 (COVID-19) caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly spread globally. Currently, Brazil has the second highest
number of deaths in the world, and is considered an epicenter of
the disease (1). The respiratory system is the primary target of the
virus, but it is increasingly recognized tomanifest in other organs,
including the kidneys. In fact, kidney involvement is relatively
common with this infection: 59% of patients present with
proteinuria, 44% with hematuria, and 10–14% with azotemia.
This is associated with increased morbidity and mortality, as this
acute renal injury can be fatal, especially when associated with
other underlying diseases (2).
Numerous morphological patterns have been described
in the kidneys of patients with COVID-19, including renal
infarction (3–5), collapsing glomerulopathy (CG) (6–10),
tubulointerstitial nephritis (11), acute tubular injury, (2, 12, 13)
acute pyelonephritis, rhabdomyolysis, lymphocytic infiltrates,
and focal segmental glomerulosclerosis (14), isometric vacuoles
in the proximal tubular epithelium (12, 14) and thrombotic
microangiopathy (TMA) (15).
Despite this, information concerning renal involvement in
COVID-19 is still scarce. Several mechanisms appear to be
involved in a complex process driven by many factors, including
the virus directly causing injury, cytokine storms, angiotensin-
II pathway activation, complement disorders, hypercoagulation
states, and microangiopathy interacting known risk factors for
acute kidney injury (AKI) (16). A more recent report on
17 patients, most with glomerular disease, favored cytokine-
mediated effects and adaptive immune responses, rather than
direct viral action, as the main mechanism underlying the
lesions associated with SARs-CoV-2. With respect to acute renal
injury, the mechanism appears to have multiple origins (17).
However, there are still effects of SARS-CoV-2 on the kidneys
that occur due currently unknown mechanisms. Therefore, any
morphological changes should be described using imaging assays
(e.g., light, fluorescent, and electron microscopy).
Furthermore, in patients with COVID-19, the morphological
patterns of kidney damage may be influenced by the ethnic
composition of each country (10). It is worth noting that almost
40% of the Brazilian population has African ancestry, which
makes Brazil the country with the second-highest percentage
of people of African descent worldwide (18). African-American
individuals have a 3- to 4-fold higher risk of end-stage
renal disease (ESRD) as compared to white individuals (19).
This may be due to the prevalence of a high-risk genotype
of apolipoprotein L-1 gene (APOL1) in this ethnic group.
Collapsing glomerulopathy is a severe form of kidney disease
related to APOL1 and has been described as COVID-19–
associated glomerulopathy (6–10).
To address all of these issues, a consortium will be conducted
involving 17 federal university hospitals belonging to the
Empresa Brasileira de Serviços Hospitalares (EBSERH) network.
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In addition, some other state hospitals and an autopsy center
in São Luís (MA, Brazil), will be participating. The aim of this
project is to assess renal morphology associated with COVID-
19 at the renal pathology reference center of federal university
hospitals in Brazil.
METHODS
Research Sites and Analysis
The EBSERH network was created to manage 42 federal hospitals
located in all states of Brazil. One of its objectives is to create
reference centers for specific services to support other hospitals.
In many of the Brazilian states, university hospitals are the only
places that perform renal biopsies for state’s public network.
Because of its adequate structure and technical qualification,
the Laboratory of Immunofluorescence and ElectronMicroscopy
(LIME) at University Hospital of the Federal University of
Maranhão (HUUFMA), located in São Luís (MA, Brazil), was
chosen as a reference center for renal pathology. Therefore, the
biopsies that are collected in all hospital units will be sent to
LIME-HUUFMA for the analysis needed for this study. They will
all be evaluated by 03 independently nephropathologist (GS, SA,
and DW).
The study will be conducted in collaboration with 24 Brazilian
health service providers that are distributed around country,
representing 14 states of the federation plus the federal district.
There will be 17 federal university hospitals, 6 state hospitals
and one center of postmortem evaluation contributing to the
study (Figure 1).
All findings will be report in a largely descriptive fashion.
Deceased Patients
Cases of deceased patients will come from five public hospitals
in Maranhão, Brazil: Federal Hospital of the Federal University
of Maranhão (HUUFMA), Women’s Hospital, Integrated Clinics
Hospital, Real Hospital, and Dr. Carlos Macieira Hospital. For
patients who died at home, a center that performs postmortem
evaluation (the Maranhão Death Verification Service, SVO-MA)
will also be involved. In these cases, lung and liver biopsies will be
collected for comparison with the changes found in the kidneys.
Placental tissue will be collected from stillborn infants. A consent
form signed by the appropriate family member was a mandatory
inclusion criterion for the study. For assessing the renal tissue of
the patients who had died, individuals of any age with a positive
PCR test result for COVID-19 were included, regardless of the
presence or absence of dysfunction. Patients whose tissue samples
were collected owing to clinical suspicion of COVID-19-related
death, but produced negative PCR test results subsequently were
excluded. Figure 2 illustrates the work flowchart for cases of
deceased patients.
Living Patients
Cases of living patients will come from 17 federal hospitals
of EBSERH, representing all five regions of the country. The
diagnosis of COVID-19 will be confirmed by performing RT-
PCR on samples (nasopharyngeal secretion or bronchoalveolar
lavage fluids), detecting the presence of SARS-CoV-2–specific
antibodies, examining radiological features, and clinical
symptoms. To standardize renal biopsy requests, an electronic
histopathological examination request system for renal biopsies
was created in 2019 to act as a national renal biopsy registry
(http://homologacao.relatorios.huufma.br/). In this system, most
information is mandatory, such as age, race, hometown, personal
and family history, clinical history, laboratory data (urinalysis,
erythrocyte dysmorphism, blood count, urea, creatinine,
24-h proteinuria, serology, autoantibodies, and fractions
complement), medications, imaging tests performed and their
results, and clinical syndrome with diagnostic hypothesis. For
this project, some mandatory requirements regarding COVID-
19 were also added: the patient must have had some infectious
symptom during the epidemic, results from serological tests,
RT-PCR for SARS-CoV-2, and imaging exams. Information
on whether kidney symptoms came before or after COVID-19
disease should also be provided. Therefore, patients infected with
SARS-CoV-2 will be divided into two groups: those who did not
have any kidney symptoms before contracting COVID-19 and
those who already had symptoms compatible with pre-existing
kidney disease. In the second group, it is important to evaluate
the impact of the disease on kidneys, which produce different
pathologies. All of these same assessments will be performed on
patients with kidney transplant. For the profile of kidney disease
established by biopsies from all of these groups will be compared
with data from the pre-epidemic periods of COVID-19. For the
patients diagnosed with CG, peripheral blood will be collected
for apolipoprotein L-1 (APOL1) genotyping. For patients with
TAM, thrombospondin type 1 motif, member 13 (ADAMTS13),
antiphospholipid and complement panel will be performed.
Other possible causes of TMA, such as autoimmune diseases,
CMV infections, EBV, and arboviruses, among others, will be
excluded by using specific tests. The workflow chart for living
patients is described in Figure 3 and summarized in Figure 1.
After signing the consent form, individuals of any age with a
positive PCR test result for SARs-CoV-2 with an indication for
renal biopsy were included in the study. Patients with clinical
suspicion of COVID-19 with a negative PCR test result were
excluded. Patients who presented with renal symptoms before,
during, or after SARs-CoV-2 infection were included in the
study for various assessments. Patients who had a significant
time interval between infection and renal biopsy were accepted
if they had the appropriate clinical history, requisite tomography
findings, and positive serology for SARs-CoV-2. Patients who did
not meet all three criteria were excluded.
Biopsy Technique, Tissue Sampling, and Processing
Ultrasound-guided percutaneous renal biopsy using 14-gauge
end-cut (for deceased patients) or 16-gauge needles (for
living patients) will be performed by nephrologists. In living
patients, three samples will be taken. In deceased patients, four
samples will be taken from each kidney with a postmortem
interval ranging from 1 to 6 h. Tissue specimens will be
fixed in Bouin solution for light microscopy (MO), Michel
solution for immunofluorescence (IF), and modified formalin
or 2.5% glutaraldehyde for electron microscopy (EM). RNAlater
solution will be used for tissue preservation for RT-PCR
Frontiers in Medicine | www.frontiersin.org 3 October 2020 | Volume 7 | Article 584235
Teixeira Júnior et al. SARS-CoV-2-Related Nephropathy
FIGURE 1 | Brazilian states consortium for studies of renal diseases associated with coronavirus disease (COVID-19). APOL1, apolipoprotein L1 gene; EM, electron
microscopy; IF, immunofluorescence; IH, immunohistochemistry; ISH, in situ hybridization; LM, light microscopy; PCR, polymerase chain reaction.
reaction for deceased patients. Only samples with 10 or more
glomeruli and at least two arteries were included in the study.
Staining for IgG, IgA, IgM, C3, C1q, fibrinogen, kappa, and
lambda will be performed using IF techniques on frozen
samples from kidney biopsies. Hematoxylin and eosin, periodic
acid–Schiff, Masson trichrome, and Jones methenamine silver
staining will be performed on paraffin-imbedded sections for
MO analysis.
Detection of SARS-CoV-2 in the Kidney
To detect SARS-CoV-2 in renal tissue, we will use
immunohistochemistry (IHC) to detect antigens and in situ
hybridization (ISH) and reverse-transcriptase polymerase chain
reaction (RT-PCR) to detect the virus’s genetic material. Samples
that produce a positive result in any of the assays will be
considered positive. In addition, these findings will be compared
with data obtained from electron microscopy, which will also be
used for virus detection.
Immunohistochemistry (IHC)
For IHC, a Dako EnvisionTM kit and PT Link (DAKO) equipment
will be used for all assays. Three micrometer-thick histological
sections will be made from biopsies samples and placed on
slides suitable for IHC. The slides will be incubated in an
oven for 30min at 60◦C to remove excess paraffin. The slides
will then be immersed in a recovery solution containing Dako
Target Retrieval Solution (10×) diluted 1:10 in distilled water
and temperature cycled in the PT Link equipment according
to the protocol provided by the supplier (i.e., pre-heating
to 65◦C; antigen recovery at 97◦C for 20min; cooling to
65◦C). The slides will subsequently be washed in Dako Wash
Buffer (1×) for 5min. After washing, the following steps are
performed: endogenous peroxidase block (5min), application
of monoclonal primary antibody against SARS-CoV-2 (1:1,000,
40143-T62; Sino Biological, Beijing, China), polymer application
(20min), 3,3
′
Diaminobenzidine (DAB) chromogen staining
(10min), Harris Hematoxylin counter-staining (5min), and slide
assembly for optical microscope analysis. Staining for various
inflammatory cells (i.e., cells that are positive for CD3, CD20,
CD4, CD8, CD138, CD68, and/or CD57) and angiotensin-
converting enzyme 2 (ACE2) (Abcam, ab15348; Cambridge, MA,
USA) will be also performed. For diagnostic purposes, some
samples will be stained with antibodies against C4d, amyloid
A, CD61, phospholipase A2 receptor (PLA2R), CD44, Wilms’s
tumor 1 (WT1), etc.
In situ Hybridization (ISH)
For detection of SARS-CoV-2 RNA in kidney tissue by ISH, the
RNAscopeTM technology (ACD, Newark, CA, USA) as previously
described by Wang et al. (20). Larsen et al. (10) used this
RNAscope to demonstrate that a COVID-19 positive patient
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FIGURE 2 | Flowchart of collection and processing of death biopsies associated with COVID-19. RT-PCR (Reverse-Transcriptase Polymerase Chain Reaction); ISH (in
situ hybridization); IHC (immunohistochemistry); MO (light microscopy); IF (immunofluorescence); EM (electron microscopy); *(collected and discarded due to a
negative RT-PCR result).
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FIGURE 3 | Flowchart of the collection and processing of living patients. RT-PCR (Reverse-Transcriptase Polymerase Chain Reaction); ISH (in situ hybridization); IHC
(immunohistochemistry); MO (light microscopy); IF (immunofluorescence); EM (electron microscopy).
with collapsing glomerulopathy did not show presence of the
SARS-CoV-2 virus in the kidney biopsy.
RT-PCR
For detection of SARS-CoV-2 in the kidney, RNA extraction will
be performed from the biopsy samples preserved in RNAlater
solution (Invitrogen, ThermoFisher Scientific, Waltham, MA,
USA). The AllPrep DNA/RNA/miRNA Universal kit (Qiagen,
Hilden, Germany) will be used for RNA isolation. RNA
concentration will be measured using the NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Rockland,
DE, USA), at wavelengths of 230, 260, and 280 nm. The RNA
integrity will be then evaluated on a 1.5% agarose gel. cDNA
synthesis will be performed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA,
USA). The samples will subsequently be subjected to detection
of SARS-CoV-2 by RT-PCR, using the protocol CDC 2019-Novel
Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
This protocol uses oligonucleotide primers and probes that were
selected from regions of the nucleocapsid (N) virus gene. The
panel was designed for specific detection of 2019-nCoV and
includes two primer/probe sets. An additional primer/probe set
will be used to detect the human RNase P gene (RP). All tests will
be performed according to the manufacturer’s specifications.
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APOL1 Genotyping of Collapsing
Glomerulopathy (CG) Cases
Blood samples will be collected after detailed explanation of
the project and its implications to the patient or relatives
and after informed consent is obtained. The consent form
will include access to all clinical and laboratorial data.
Genomic DNA will be extracted from blood samples using
the QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany)
and DNA samples will be stored at −20◦C. Quantification
and quality analysis of DNA will be performed using
NanoDrop 2000/c Spectrophotometer (ThermoFisher Scientific,
Waltham, MA, USA). Polymerase chain reaction (PCR)
will be performed with the oligonucleotides APOL1_7F (5′-
CCAACTTTCTTTCCTTAGCTGGC-3′) and APOL1_7R
(5′-TCACAGTTCTTGGTCCGCC-3′) as well as a PCR Master
Mix kit (Promega, Madison, WI, EUA), in cycle conditions as
described: 95◦C for 5min; 95◦C for 30 s, 60◦C for 30 s, and
72◦C for 1min (35 cycles); and 72◦C for 10min. Following PCR,
5 µL of each product will be subjected to electrophoresis on
a 20% agarose gel and the amplicons will be identified based
on the expected molecular weight. Th PCR product will be
purified with Agencourt AMPure XP kit (Beckman Coulter
Life Sciences, Indianapolis, IN, USA). Sanger sequencing will
be performed with BigDye Terminator Cycle Sequencing
Ready Reaction Kit version 3.1 (Applied Biosystems, Foster
City, CA, USA) and an ABI Prism 3130XL automated
sequencer (ThermoFisher Scientific, Waltham, MA, USA).
The sequences will be compared with reference sequences
(NG_023228) and confirmed by reverse strand sequencing.
Data analysis will be performed with Software Chromas
2.6.6 (http://www.technelysium.com.au).
DISCUSSION
Renal involvement is common in cases of COVID-19. Previous
studies have reported that up to 29% of infected patients
may develop AKI and up to 59% of patients may develop
proteinuria, which increases the risk of death (2, 21). Su et al.
(14) propose that the disease induces early development of
defective proteinuria and damages kidney tubular function. The
mechanism by which this occurs remains unclear. Sepsis, acute
tubular necrosis, cytokine storms, direct viral action, thrombosis,
and rhabdomyolysis may be possible causes. ACE2 provides the
entry point for SARS-CoV-2 to attach to and infect human cells;
ACE2 is expressed on podocytes, vascular endothelial cells and
proximal tubule cells. The ability of these different kidney cells to
be infected may explain injuries develop in various parts of the
kidneys (2–14).
In the literature, the presence of SARS-CoV-2 has been
demonstrated using different techniques. Diao et al. (16)
described the presence of syncytia as a finding associated
with COVID-19 infection. Other authors, however, have not
confirmed this finding (14). Moreover, viral particles can be
difficult to unequivocally identify with EM. Additionally, the
appearance of intracellular viral inclusions appears vary quite
from one publication to another and must be differentiated
from other structures present in the kidney tissue, mainly
due to autolytic effects (22). In our study, all autopsies will
be performed with a postmortem interval of <6 h, which
might be short enough to prevent significant autolysis. Antigen
detection by IHC is a very limited technique; this can be
partly overcome with the aid, of other assays such as in
situ hybridization. Detection of virus within renal cells by
electron microscopy has been proposed as a straightforward
approach to demonstrate direct renal involvement. However, for
most authors, the identification of direct infection by SARS-
CoV-2 does not exclude other mechanisms of renal injury
in COVID-19 patients. In a case series reported by Kudose
et al., electron microscopy, immunostaining for viral spike
and nucleocapsid proteins, and ISH for viral RNA using an
automated platform failed to demonstrate the presence of viral
particles in renal tissue. The results of manual ISH were
doubtful. However, the authors did not perform PCR, which
is considered to have higher sensitivity for detecting viral
material (17). Therefore, it is vital to use multiple techniques
for reliable viral detection and to establish the role of direct
viral action in different morphological patterns. Larger studies,
such as the one we are currently proposing, on kidney
biopsies of patients with COVID-19 are needed to definitively
confirmed or rule out the existence of a possible SARS-CoV-
2 nephropathy.
After the spread of the epidemic in the United States,
reports of an association between collapsing glomerulopathy
(a kind of podocytopathy), and SARS-CoV-2 infection were
made. In some cases, the high-risk allele of APOL1 was
found; as previously described, this allele is present mainly in
populations of African ancestry (7, 10). The large percentage
of Afro-descendants present in the American population may
explain why these types of cases did not occur in Asian
and some European countries. It appears likely that in Afro-
descended individuals with high-risk APOL1 variants, SARS-
CoV-2 infection acts as a “trigger” that leads to podocyte
dysregulation and injury, which leads to CG. For some
authors, however, this association may be just a coincidence
(13) and the presence of the virus in podocytes may
be an incidental finding. Moreover, a recent report of
postmortem kidney tissue analysis from 6 patients who died
of COVID-19 showed acute tubular injury without glomerular
abnormalities (14).
Brazil is a country with a large population of Afro-
descendants (around 40% of all Brazilians) (18) and the
APOL1 high-risk genotype found in Brazil was considered
responsible for a more aggressive disease phenotype (23). In
addition, the considerable genetic heterogeneity of the Brazilian
population and the wide range of possible microenvironments
may be highly advantageous for the study of genetic and
environmental aspects associated with APOL1. These factors,
along with Brazil’s current critical situation in the face
of the COVID-19 pandemic, make it the ideal country
for conducting studies that assess the likely existence of
a SARS-CoV-2-nephropathy.
AKI induced by SARS-CoV-2 also affects patients with
previous renal disorders. Studies claim that chronic kidney
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FIGURE 4 | Renal morphologic patterns in COVID-19 patients from Empresa Brasileira de Serviços Hospitalares (EBSERH) network. (A) Needle biopsy in a male
patient (aged 43 years) shows glomerulus with tuft collapse and overlying epithelial hypertrophy and hyperplasia compatible with collapsing glomerulopathy (Masson
Trichrome stain; original magnification ×400). (B) Needle biopsy in a young male patient (aged 30 years) shows arterioles with intimal thickening and large luminal
thrombus compatible with thrombotic microangiopathy (Masson Trichrome stain; original magnification ×400). Barr = 20µm.
disease (CKD) is associated with severe disease in those
affected by COVID-19 (24). However, there are no large studies
analyzing the impact of SARS-CoV-2 infection on patients
with glomerulopathies; there are only case reports (25). Kidney
transplant recipients appear to be a particularly high-risk group
for critical COVID-19 illness due to chronic immunosuppression
and coexisting conditions (25). Therefore, the impact of COVID-
19 infection on transplant patients and patients followed
up with on an outpatient basis will also be analyzed in
our study.
In initial reports, renal injury was always associated with
a severe pulmonary component. However, cases were later
reported where renal injury did not depend on pulmonary
involvement (24). In the present study, fragments of lung and
liver will also be collected and the results will be compared
with kidney specimens. With these results we hope to better
understand the role of the coronavirus in the appearance and
evolution of kidney injuries.
Here we included two morphological pictures described as
SARS-Cov-2 nephropathy: a CG and a TMA (Figure 4). The
two patients come from different hospitals from the Empresa
Brasileira de Serviços Hospitalares (EBSERH) network. Both had
a clinical picture compatible with COVID-19 and PCR was
positive for SARS-CoV-2. The renal symptoms were noted after
presentation of the symptoms of COVID-19 and both patients
showed pulmonary involvement.
CONCLUSION
Kidney injuries caused by SARS-CoV-2 are frequent and impact
on morbidity and mortality, but considerable doubts remain
about the likely injuries and their mechanisms. Ultimately, this
work from the morphological point of view can help to define
the spectrum and impact, whether immediate or long-term, of
kidney injury caused by SARS-CoV-2.
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